RCS - OptiBiotix Health - UK Investor Show attendance <Origin Href="QuoteRef">OPTIO.L</Origin>

OptiBiotix HealthAnnouncement

29/03/2017 10:50

RNS Number : 8855A
OptiBiotix Health PLC
29 March 2017
OptiBiotix Health plc
("OptiBiotix" or the "Company")
UK Investor Show attendance
OptiBiotixHealthplc(AIM:OPTI),alifesciencesbusinessdevelopingcompoundstotackleobesity,high cholesterol,diabetes and skin care, announce that they will be participating in the UK Investor Show 2017.
The event is taking place on 1 April 2017 at the Queen Elizabeth II Conference Centre in Westminster, London SW1P 3EE. The team will be available from 8:30am until 5:30pm to discuss recent events for the Company as well as their strategy for accelerating growth. The OptiBiotix team will be at Booth 106. 
For further information, please contact:
OptiBiotix Health plc
www.optibiotix.com
Stephen O'Hara, Chief Executive
Contact via Walbrook below

Walbrook PR Ltd
Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy
 Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com 
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease. 
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes. 
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen and OptiBiotic platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases. 

This information is provided by RNS
The company news service from the London Stock Exchange
  END
NRALIFSAVFIAFID